States of Pluripotency: Naïve and Primed Pluripotent Stem Cells

Daman Kumari

Abstract

Pluripotent stem cells are classified into naïve and primed based on their growth characteristics in vitro and their potential to give rise to all somatic lineages and the germ line in chimeras. In this chapter, I describe the similarities and differences between the naïve and primed pluripotent states as exemplified by mouse embryonic stem cells (mESCs), mouse epiblast stem cells (mEpiSCs), human embryonic stem cells (hESCs), and human induced pluripotent stem cells (hiPSCs). I also review the efforts for derivation of naïve human pluripotent stem cells by manipulating culture conditions during reprogramming of somatic cells and attempts to revert primed hESCs to the naïve state. Understanding the requirements for induction and maintenance of the naïve pluripotent state will facilitate studies on early human embryonic development and understanding the mechanisms involved in X inactivation in vitro. In addition, the development of naïve hiPSCs will improve the efficiency of gene targeting for the purpose of modeling human diseases as well as for generating gene-corrected autologous pluripotent stem cells for regenerative medicine.

Keywords: naïve, primed, pluripotent stem cells, epigenetic, fragile X syndrome

1. Introduction

Two distinct pluripotent states are observed in embryonic stem cells from mice: the ground or naïve state, exemplified by the mouse embryonic stem cells (mESCs) [1], and the primed pluripotent state represented by mouse epiblast stem cells (mEpiSCs) [2,3]. The clearest difference between the two states is colony morphology, growth factor requirement for maintenance of the pluripotent state, and X inactivation status in female cells. Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) identify...
more closely with mEpiSCs than mESCs [4]. Understanding the requirements for induction and maintenance of the naïve pluripotent state for human stem cells will facilitate their application for studying early embryonic development, disease modeling, drug screening, and cell-based therapies.

In this chapter, I mention the similarities and differences between naïve and primed pluripotent stem cells (PSCs) and describe various strategies that have been utilized for the derivation of naïve human PSCs and/or reversion of primed state stem cells to the naïve-like ground state. I also discuss how the availability of naïve hESCs and hiPSCs will further the mechanistic studies of various biological phenomena and facilitate genetic manipulations of hPSCs for disease modeling as well as regenerative medicine.

2. Characteristic features of the naïve and primed pluripotent stem cell states

Embryonic stem cells in mice exist in two functionally distinct pluripotent stem cell states. Specifically, mESCs that are derived from the inner cell mass (ICM) of preimplantation embryos represent naïve pluripotent stem cells (PSCs). These cells have an unlimited self-renewal capacity when grown under appropriate conditions and are able to differentiate into tissues of all three germ layers in vitro. In addition, when injected back into the early embryos, naïve stem cells contribute to all somatic lineages including the germline. This ability to generate chimeras is indicative of their pluripotency in vivo. On the other hand, mEpiSCs that are derived from the epiblast of the post-implantation embryo typify the primed state. Also included in this category are hESCs and hiPSCs that resemble closely the mEpiSCs, even though they are isolated from preimplantation embryos. Like the naïve PSCs, the primed PSCs also have unlimited potential to self-renew and differentiate into three germ layers in vitro, but are limited in their pluripotency in vivo, as they cannot give rise to germline chimeras [5]. The naïve mESCs typically grow as small, compact, domed colonies, whereas the primed mEpiSC colonies are large and grow as monolayer similar to hESCs. In addition, naïve cells survive better than their primed counterparts when passaged as single cells and have a shorter doubling time [3]. The naïve and primed PSCs also use different modes of respiration for generating energy. While metabolism in naïve stem cells utilizes both oxidative phosphorylation (mitochondrial respiration) and glycolysis, primed cells preferentially generate energy through the glycolytic pathway [6].

Another key feature of the naïve state in mESCs is that both X chromosomes are active in female cells and undergo random X chromosome inactivation (XCI) upon differentiation in vitro. In contrast, XCI has already been established in primed mEpiSCs and this feature can thus be used as a reliable marker to distinguish between the two pluripotent states in female stem cells. The XCI status can also be used to identify the optimal culture conditions for maintenance of the naïve stem cell state and for monitoring the epigenetic stability of human PSCs [4]. Other epigenetic differences between the two murine pluripotent states include global DNA hypomethylation [7, 8], reduced prevalence of the repressive histone mark H3K27me3 at promoters, and fewer bivalent domains in naïve ESCs [9]. The key features of naïve and primed PSCs are summarized in Table 1.
| Property                                      | Naïve state                                                                 | Primed state                                                                 |
|----------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Origin                                       | ICM of early blastocyst                                                       | Post-implantation epiblast (Egg cylinder) or embryonic disc                  |
| Representative examples                      | mESCs, miPSCs                                                                | mEpiSCs, hESCs, hiPSCs                                                       |
| Expressed genes\(^1\)                        | High expression of Oct4, Nanog, Sox2, Klf2, Klf4, Klf5, Zpf42, Esrrb, Dppa3, Tfcp2l1, Fgf4, Tbx3, Cdh1 | Oct4, Sox2, Dmnt3b, Fgf5, Pou3f1, Meis1, Otx2, Sox11, Gdf3                  |
| Colony morphology                            | Compact dome shaped                                                          | Flattened                                                                    |
| Differentiation bias                         | None                                                                         | Variable                                                                     |
| Tearatomas                                   | Yes                                                                          | Yes                                                                          |
| Chimeric contribution in rodents\(^2\)       | Yes                                                                          | No                                                                           |
| Clonogenicity                                 | High                                                                         | Low                                                                          |
| Single-cell mortality                        | Low                                                                          | High                                                                         |
| Growth factor dependence                     | LIF                                                                          | ACTIVIN, FGF2                                                                |
| Respiration                                  | Oxidative phosphorylation, glycolysis                                        | Glycolysis                                                                   |
| XCI status in female cells \(^3\)            | XaXa                                                                         | XaXi                                                                         |
| Oct4 enhancer usage                          | Distal                                                                       | Proximal                                                                     |
| Global DNA methylation                       | Hypomethylated                                                               | Hypermethylated                                                              |
| Response to LIF/stat3                        | Self-renewal                                                                 | None                                                                         |
| Response to Fgf/Erk                           | Differentiation                                                              | Self-renewal                                                                 |
| Response to 2i                                | Self-renewal                                                                 | Differentiation                                                              |
| Level of HERVH\(^4\) expression             | High                                                                         | Low                                                                          |
| Efficiency of gene targeting                 | High                                                                         | Low                                                                          |
| H3K27Me3 over developmental regulators       | Low                                                                          | High                                                                          |
| TFE3 localization                            | Nuclear                                                                      | Cytoplasmic/absent                                                           |

\(^1\)Gene expression changes are based upon murine PSCs.

\(^2\)Chimera assays are not always possible for hPSCs due to ethical concerns.

\(^3\)HERVH expression is seen only in hPSCs.

Table 1. Characteristic features of naïve and primed pluripotent stem cell states.

Much of what we know about the growth factor dependence of naïve and primed PSCs is based on studies performed with mESCs and mEpiSCs. Mouse ESCs can be maintained long term in the naïve state when cultured in the presence of serum plus leukemia inhibitory factor
(LIF), which signals through a bipartite receptor to activate Janus-associated kinases (JAK) which leads to the activation of signal transducer and activator of transcription 3 (Stat3) [10]. However, in the absence of serum, LIF alone is unable to prevent differentiation of mESCs. This limitation is overcome by the addition of two small molecule kinase inhibitors termed “2i” with LIF. The 2i components include a specific inhibitor of extracellular signal-regulated kinase (ERK1/2)/mitogen-activated protein kinase (MAPK) signal transduction pathway (MEKi, PD0325901) and a specific inhibitor of glycogen synthase kinase 3 beta (GSK3βi, CHIR99021) that protect the ESCs from pro-differentiation stimuli and select against differentiating cells [11]. The most critical effects of GSK3i are mediated via β-catenin, which is the key mediator of Wnt/β-catenin signaling pathway. While fibroblast growth factor (FGF)-mediated activation of MEK signaling drives differentiation of mESCs, primed mEpiSCs require basic fibroblast growth factor (bFGF or FGF2) and are dependent on the activin/nodal pathway for the maintenance of pluripotency [3]. Similar to the mEpiSCs, human PSCs do not require LIF but are dependent on bFGF and activin/transforming growth factor β-1 (TGFβ1) for their long-term maintenance in culture [12, 13]. However, as discussed later, it is possible to revert primed hPSCs to the naïve state using LIF/2i.

Naïve mESCs and primed mEpiSCs also differ in the expression of pluripotency-associated transcription factors. While the pluripotency factors Oct4/Pou5f1 and Sox2 are expressed in both naïve and primed murine PSCs, factors like Nanog, Klf2, Klf4, Prdm14, Sall4, Tcfcp211, Esrrb, and Tbx3 are preferentially expressed or upregulated in the naïve mESCs. In addition, Tfe3, which is localized in the nucleus of naïve PSCs, becomes cytoplasmic upon their conversion to the primed state and results in reduced expression of Esrrb [14]. The forced expression of naïvity-associated transcription factors has been shown to convert the primed iPSCs into the naïve state suggesting their importance for the propagation of the ground state [15]. Although conventional hPSCs functionally resemble the primed pluripotent state of mEpiSCs, they are not identical and show specific differences in transcription regulation and the expression of various markers like FGF5, E-CADHERIN, and NANOG (reviewed in [16]).

3. Strategies for the generation of naïve human pluripotent stem cells

The naïve pluripotent state of mESCs is also observed in PSCs derived from rat embryos [17, 18]. However, naïve PSCs were not observed in other species in this study and it was not clear if this was a feature only of rodent ESCs or if it would be possible to capture it in other species. In recent years, naïve-like stem cells have been isolated from porcine fibroblasts [19], rhesus monkey fibroblasts [20], rabbit embryos, liver and stomach [21], finch embryos [22], and bovine amnion-derived cells [23]. In addition, several reports of the successful derivation of human PSCs resembling naïve mESCs in morphology and gene expression signatures have also been published [24–32]. This confirms that the naïve-like pluripotent state is not species specific as originally assumed to be limited to rodents, but may reflect an early developmental stage conserved across mammalian and possibly vertebrate evolution. The ability to capture human
PSCs in the naïve state opens up a plethora of opportunities for their use in disease modeling and regenerative medicine.

| Reference                  | Method used                                                        | Growth factors in medium | XCI status | Chimera assay |
|---------------------------|--------------------------------------------------------------------|---------------------------|------------|---------------|
| Hanna et al. 2010 [24]    | Sustained or transient expression of OCT4, SOX2, KLF4 or KLF2     | LIF/2i or LIF/2i/FK or LIF/2i | Pre-XCI    | ND            |
| Gafni et al. 2013 [26]    | Small molecules                                                    | LIF/2i/bFGF/TGFβ/JNKi/p38i/ROCKi | Pre-XCI    | Positive      |
| Chan et al. 2013 [25]     | Small molecules                                                    | LIF/2i/BMPi/bFGF/TGFβ/ROCKi | ND         | ND            |
| Takashima et al. 2014 [27]| Sustained or transient expression of NANOG and KLF2               | LIF/2i/Go-6983            | Pre-XCI    | ND            |
| Valamehr et al. 2014 [29] | Small molecules                                                    | LIF/2i/bFGF              | Pre-XCI    | ND            |
| Theunissen et al. 2014 [28]| Selection based on OCT4 distal LIF/5i/bFGF/ ActivinA enhancer activity | XaXi                      | XaXi       | negative      |
| Wang et al. 2014 [35]     | Selection of HERVH expressing cells                               | LIF/2i/bFGF              | Pre-XCI    | ND            |
| Ware et al. 2014 [30]     | Small molecules                                                    | 2i/bFGF                  | ND         | ND            |
| Duggal et al. 2015 [31]   | Small molecules                                                    | LIF/2i/bFGF/FK/AA        | ND         | ND            |
| Yang et al. 2016 [34]     | Small molecules                                                    | LIF/5i/bFGF/ActivinA     | ND         | Positive      |
| Carter et al. 2016 [32]   | Recombinant protein                                                | NME7AB                   | Pre-XCI    | ND            |

FK, forskolin; AA, ascorbic acid; Xa, active X; Xi, inactive X; XCI, X chromosome inactivation; ND, not done.

Table 2. Summary of various protocols used for generating naïve human pluripotent stem cells.

Naïve-like human PSCs have been obtained either by forced expression of pluripotency transcription factors or by using various combinations of small molecules and/or growth factors to improve the culture conditions for inducing and maintaining naïve stem cell characteristics (Table 2). Buecker and colleagues described the derivation of hiPSCs in the presence of LIF and five ectopic reprogramming factors, OCT4, SOX2, KLF4, cMYC, and NANOG (called hLR5 iPSCs), that displayed morphological, molecular, and functional properties of mESCs [33]. In another study, the Jaenisch group showed that the ectopic induction of OCT4, KLF4, and KLF2 in hESCs grown in 2i/LIF media resulted in naïve stem cells that resembled mESCs in their gene expression profile and reactivation of both X chromosomes [24]. One limitation of this approach is that continuous expression of the pluripotency factors was required for maintenance of the ground state in the resultant PSCs.
thereby restricting their potential for downstream applications. To overcome this limitation, several groups have used small molecules to achieve transgene-independent derivation of naïve hPSCs. Using a reporter cell line containing a doxycycline (dox)-inducible OCT4-Green Fluorescent Protein (OCT4-GFP) reporter, Gafni et al. [26] identified a combination of factors that facilitated the derivation of genetically unmodified naïve hESCs from blastocysts, hiPSCs from somatic cells, as well as the reverse toggling and maintenance of primed hESCs into the naïve state. This naïve human stem cell medium (NHSM) included essential components [2i/ LIF, TGFβ1, c-Jun N-terminal kinase inhibitor (JNKi, SP600125), p38i (SB203580)] and optimizing components [Rho kinase inhibitor (ROCKi, Y-27632) and protein kinase C inhibitor (PKCi, Go6983)] for supporting the growth of naïve hPSCs [26]. These naïve-like hiPSCs grown in NHSM showed higher integration into chimeras compared to the primed PSCs. In another study, Chan et al. [25] screened 11 small molecules for their ability to increase NANOG expression and identified a combination of three inhibitors [2i plus a bone morphogenetic protein (BMP) inhibitor, dorsomorphin] in TeSR1 base medium and LIF that maintained hESCs in the ground state. The authors observed an upregulation of a number of genes that are expressed in human preimplantation embryos in the hESCs grown in 3i/LIF medium compared to the conventionally cultured hESCs. Valamehr et al. [29] also reported the derivation and maintenance of transgene-free hiPSCs with naïve-like characteristics using fate maintenance medium (FMM) that contains 2i/LIF in conventional hESC medium. These cells showed high survival rates in single-cell dissociation and displayed the characteristics of a pre-XCI state with decreased levels of XIST and H3K27me3. In contrast, Ware et al. [30] were able to reverse toggle primed hESCs by preculture in the histone deacetylase inhibitors, sodium butyrate, and suberoylanilide hydroxamic acid, followed by culture in 2i with bFGF in the absence of LIF. In addition, they reported the derivation of naïve hESCs only in the presence of 2i and bFGF.

To more systematically identify optimal culture conditions for the induction and maintenance of naïve human pluripotency, Theunissen et al. [28] screened a kinase inhibitor library using a specific reporter system based on the activity of the endogenous OCT4 distal enhancer that is exclusively active in the naïve pluripotent state. They described a serum-free N2B27 medium supplemented with five kinase inhibitors (MEKi, GSK3βi, BRAFi, LCK/SRCi, ROCKi), LIF, bFGF, and activin A (5i/L/FA) that was sufficient to maintain naïve hESCs in culture. Cells grown under these conditions showed a dramatic upregulation of transcription factors typically associated with naïve pluripotency and human preimplantation development. However, abnormal karyotype in several converted and newly derived hESC lines in 5i/L/FA was observed leading to the authors’ suggestion that naïve hPSCs may be more prone to acquiring chromosomal abnormalities. In addition, in this study, hESCs grown either in the 5i/L/FA medium or as per the Gafni et al. protocol [26] did not form interspecies chimeras efficiently. The authors attributed this discrepancy between the two studies to slight variations in culture conditions or embryo handling. Furthermore, female hESCs grown under 5i/L/FA conditions showed an upregulation of XIST and XCI upon conversion from the primed state. These features illustrate the limitation of hPSCs derived in 5i/L/FA medium or, as suggested by the authors, this may highlight the differences in the naïve pluripotent state between human and mouse. Using this 5i/L/FA medium, naïve iPSCs could be generated from fibroblasts.
derived from β-thalassemia patients in whom the genetic mutation was corrected by CRISPR/Cas9 gene editing [34]. More recently, Duggal et al. [31] reported the formulation of yet another culture medium that facilitated the rapid, robust, and efficient induction of naïve pluripotency in primed hESCs. In addition to the 2i/LIF, the authors included ascorbic acid (known to induce DNA demethylation and enhance reprogramming), forskolin (an activator of cAMP, shown to promote naïve pluripotency), and different concentrations of bFGF in the culture medium to identify optimal conditions for converting primed hESC lines toward a naïve state of pluripotency.

Another method, based on the selection of cells with naïve-like characteristics from a heterogeneous population of naïve and primed PSCs, has been published. Since LTR7/human endogenous retrovirus, HERVH, expression was found to be required for maintaining pluripotency in hPSC, Wang et al. developed an LTR7-driven GFP reporter construct to tag, select, and maintain naïve-like hPSCs [35]. By using this reporter, the authors were able to sort and enrich for LTR7-GFP-expressing cells and thus maintain a homogeneous population of naïve-like hPSCs over the long term. The hPSCs selected based on high expression of HERVH shared many features with naïve mESCs that included 3D rounded colonies, reactivation of the X chromosome in female cells, and uniform expression of core pluripotency transcription factors with downregulation of genes expressed in differentiated cells. Moreover, these cells grew faster and had improved cloning capacity making them suitable for genetic manipulation. However, the level of HERVH expression was found to be an important determinant of the ability of the stem cells to differentiate with higher levels of HERVH interfering with the differentiation potential. The LTR7-GFP reporter could be useful for further optimization of culture conditions for the maintenance of naïve pluripotent state for human stem cells.

Although it is possible to generate human PSCs with features that are characteristic of naïve mESCs by culturing them in the presence of exogenous factors or a cocktail of small molecules, their tendency to develop karyotypic abnormalities in long-term culture [28] raises concerns that these may not be the true, naturally occurring human naïve stem cells. To capture this natural naïve state of hPSCs without additional growth factors or small molecules, Carter et al. [32] developed a novel approach using a naturally occurring human growth factor, NME7, in minimal media without bFGF, LIF, or any other small molecule. NME7 belongs to the NME family of nucleotide phosphate kinases but lacks the kinase activity. It is proposed to act by binding to the MUC1* growth factor receptor that is expressed on the surface of stem cells and results in its dimerization which promotes growth and pluripotency. The hPSCs grown in the presence of NME7, recombinant human NME7 protein, grew faster, showed resistance to differentiation, demonstrated increased cloning efficiency, had two active X chromosomes in the female cells, and had a normal karyotype after 30 or more passages. However, NME7-derived cells did not form colonies and grew preferentially as a monolayer. The various strategies used for the derivation of naïve-like hPSCs are summarized in Table 2.

While all of the above-mentioned approaches claim to have successfully derived the so-called ground state naïve-like hPSC, the resultant cells do not share the same gene expression patterns, although there is some overlap [32]. Therefore, a set of core genes/markers that clearly define naïve hPSCs is not currently available but is highly desirable.
4. Naïve hPSCs for gene targeting and regenerative medicine

The ability to generate homogeneous populations of stable naïve hPSCs that have the potential to differentiate equally toward all lineages will be critical for their use in disease modeling and regenerative medicine. The faster doubling time of naïve PSCs and their capacity for clonal expansion is important for generating large number of cells required for screening applications. Marked differences in the propensity of hESCs to differentiate into certain lineages or cell types have been reported [36]. Additionally, hiPSCs generated using conventional methods were shown to be limited in their proficiency of lineage-specific differentiation that can be influenced by the donor cell type [37]. However, new data show that the differentiation propensities of hiPSCs are significantly biased by donor-dependent variability and not by cell type of origin [38]. It has been suggested that the conversion of hiPSCs to a more naïve-like state could improve their in vitro differentiation potential toward specific cell types by resetting their epigenetic status [39, 40]. However, a systematic study to directly compare the differentiation efficiency of isogenic naïve and primed hPSCs into different cell types has not been done and will be necessary to establish that naïve hiPSCs have a better differentiation ability than their primed counterparts. It has been observed that the efficiency of homologous recombination is significantly higher in mESCs in comparison to hESCs and hiPSCs [41, 26], suggesting that the PSCs in the naïve state might be more amenable to gene editing. In addition, the very low clonal efficiency and slow growth rate of primed hPSCs limit the full potential of gene targeting mediated by site-specific nucleases, thereby supporting the generation of naïve PSCs for efficient gene editing. Hu et al. [42] converted primed state iPSCs from Parkinson's disease patients to a so-called “naivetropic” state by dox-induced expression of transgenes (OCT4, SOX2, KLF4, c-MYC, and NANOG) and the use of LIF/2i. Using these cells, they were able to target GFP to the PITX3 locus by transcription activator-like effector nuclease (TALEN) very efficiently. Similarly, Yang et al. [34] showed significant improvement in the mutation correction efficiency in naïve hiPSCs derived from β-thalassemia patients using the 5i/L/FA system [28].

5. Naïve hPSCs for studying the process of X inactivation during early human embryonic development

In addition to the therapeutic potential of pluripotent stem cells for drug screening and regenerative medicine, their ability to recapitulate early embryonic differentiation is useful for study of the pathways involved in cell commitment and embryonic differentiation. One such process that is developmentally regulated and tightly linked with cell differentiation is the random inactivation of one of the two X chromosomes in all of the cells in female mammals that balances the sex difference in dosage of X-linked genes. This is a highly coordinated and stepwise process involving many noncoding RNAs that affect epigenetic modifications and cause transcriptional silencing of the entire X chromosome barring a few genes that escape silencing (see [43] for a recent review on the subject). Most of what we know about the mechanism of XCI comes from many elegant studies done with mice and has benefited from
the existence of naïve state mESCs with two active X chromosomes that undergo random XCI upon further differentiation. However, there are distinct differences between the XCI process in mice and humans (reviewed in [44]). For example, the imprinted inactivation of the paternal X chromosome seen in the early mouse embryo and maintained in the placenta does not occur in human embryo [45] which only exhibit random XCI. In addition, some of the genes that escape XCI in humans are inactivated in mice [46] and substantial diversity in the timing and regulation of XCI between mammals has been observed [47]. Therefore, having the ability to model XCI using hESCs or hiPSCs is highly desirable and will definitely benefit from optimized methods to derive and maintain female hESCs or hiPSCs in the naïve state with two active X chromosomes.

6. Naïve hPSCs for in vitro modeling of human diseases

Human PSCs can be used to study underlying mechanisms of diseases that cannot be modeled easily in mice. One such example is the repeat-mediated aberrant silencing of the *fragile X mental retardation 1 (FMR1)* gene in fragile X syndrome (FXS). FXS is the most common cause of inherited intellectual disability and autism spectrum disorder [48]. The most common mutation in FXS is the expansion of a CGG-repeat tract in the 5′-untranslated region of the *FMR1* gene that causes its transcriptional silencing by DNA methylation and heterochromatin formation [49, 50]. It is believed that the repeat-mediated *FMR1* gene silencing is developmentally regulated with the gene being active in the early embryo and silenced at a later time during development (see [51] for a recent review). Mouse models for the expanded CGG repeats do not result in *Fmr1* gene silencing [52, 53] and therefore cannot be used for studying the underlying mechanism of gene silencing in FXS or its effect on the developing brain. In the first reported FXS embryonic stem cell line, the *FMR1* gene was active in the ESCs and showed silencing upon differentiation into embryoid bodies [54]. This generated a great interest in developing stem cells as a model to study the mechanisms involved in gene silencing. However, in most of the subsequently generated FXS ESCs, the *FMR1* gene is already silenced [55, 56]. Additionally, iPSCs generated from FXS patient fibroblasts do not show reactivation of the *FMR1* gene [57]. Using a strategy that would favor the generation of naïve iPSCs, Gafni et al. [26] were able to derive naïve state FXS iPSCs that had an active *FMR1* gene. These observations lend support to the idea that the *FMR1* gene is active in the very early embryo but that silencing occurs very soon after that perhaps associated with the transition to the primed state. A better understanding of this process may allow the modeling of developmental silencing of the *FMR1* gene **in vitro**. In addition, these studies will also illuminate the general process by which heterochromatin might be reset during the process of reprogramming cells to pluripotency.

7. Conclusions

Recent research suggests that it might be possible to achieve naïve pluripotency of hESCs and hiPSCs by using specific combinations of small molecule inhibitors and growth factors in the
culture medium during their derivation and growth. The ability to generate and maintain naïve pluripotent stem cells will facilitate studies on early human embryonic development and the mechanisms involved in XCI \textit{in vitro}. This will also improve the odds of genetically correcting mutations that cause human diseases and thus help in dissecting the mechanisms of disease pathogenesis. In addition, the ability to stably maintain the epigenetic state of the pluripotent stem cells will be critical for their use in stem cell-based gene therapies.

**Acknowledgements**

I thank Karen Usdin and Yifan Zhou (Laboratory of Cell and Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health), Barbara Mallon (NIH Stem Cell Unit, National Institute of Neurological Disorders and Stroke), and James Kehler (Special volunteer at the National Institutes of Health) for critical reading of the manuscript and helpful discussions.

**Author details**

Daman Kumari

Address all correspondence to: damank@helix.nih.gov

Laboratory of Cell and Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA

**References**

[1] Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154–6.

[2] Brons IG, Smithers LE, Trotter MW, Rugg-Gunn P, Sun B, Chuva de Sousa Lopes SM et al. Derivation of pluripotent epiblast stem cells from mammalian embryos. Nature. 2007;448(7150):191–5. doi:10.1038/nature05950.

[3] Tesar PJ, Chenoweth JG, Brook FA, Davies TJ, Evans EP, Mack DL et al. New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature. 2007;448(7150):196–9. doi:10.1038/nature05972.

[4] Nichols J, Smith A. The origin and identity of embryonic stem cells. Development. 2011;138(1):3–8. doi:10.1242/dev.050831.
[5] Huang Y, Osorno R, Tsakiridis A, Wilson V. In vivo differentiation potential of epiblast stem cells revealed by chimeric embryo formation. Cell Rep. 2012;2(6):1571–8. doi: 10.1016/j.celrep.2012.10.022.

[6] Teslaa T, Teitell MA. Pluripotent stem cell energy metabolism: an update. Embo J. 2015;34(2):138–53. doi:10.15252/embj.201490446.

[7] Ficz G, Hore TA, Santos F, Lee HJ, Dean W, Arand J et al. FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency. Cell Stem Cell. 2013;13(3):351–9. doi:10.1016/j.stem.2013.06.004.

[8] Habibi E, Brinkman AB, Arand J, Kroeze LI, Kerstens HH, Matarese F et al. Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell. 2013;13(3):360–9. doi:10.1016/j.stem.2013.06.002.

[9] Marks H, Kalkan T, Menafra R, Denissov S, Jones K, Hofemeister H et al. The transcriptional and epigenomic foundations of ground state pluripotency. Cell. 2012;149(3):590–604. doi:10.1016/j.cell.2012.03.026.

[10] Niwa H, Ogawa K, Shimosato D, Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature. 2009;460(7251):118–22. doi:10.1038/nature08113.

[11] Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J et al. The ground state of embryonic stem cell self-renewal. Nature. 2008;453(7194):519–23. doi:10.1038/nature06968.

[12] James D, Levine AJ, Besser D, Hemmati-Brivanlou A. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development. 2005;132(6):1273–82. doi:10.1242/dev.01706.

[13] Levenstein ME, Ludwig TE, Xu RH, Llanas RA, VanDenHeuvel-Kramer K, Manning D et al. Basic fibroblast growth factor support of human embryonic stem cell self-renewal. Stem Cells. 2006;24(3):568–74. doi:10.1634/stemcells.2005-0247.

[14] Betschinger J, Nichols J, Dietmann S, Corrin PD, Paddison PJ, Smith A. Exit from pluripotency is gated by intracellular redistribution of the bHLH transcription factor Tfe3. Cell. 2013;153(2):335–47. doi:10.1016/j.cell.2013.03.012.

[15] Guo G, Yang J, Nichols J, Hall JS, Eyres I, Mansfield W et al. Klf4 reverts developmentally programmed restriction of ground state pluripotency. Development. 2009;136(7):1063–9. doi:10.1242/dev.030957.

[16] Weinberger L, Ayyash M, Novershtern N, Hanna JH. Dynamic stem cell states: naive to primed pluripotency in rodents and humans. Nat Rev Mol Cell Biol. 2016;17(3):155–69. doi:10.1038/nrm.2015.28.
[17] Buehr M, Meek S, Blair K, Yang J, Ure J, Silva J et al. Capture of authentic embryonic stem cells from rat blastocysts. Cell. 2008;135(7):1287–98. doi:10.1016/j.cell.2008.12.007.

[18] Li P, Tong C, Mehrian-Shai R, Jia L, Wu N, Yan Y et al. Germline competent embryonic stem cells derived from rat blastocysts. Cell. 2008;135(7):1299–310. doi:10.1016/j.cell.2008.12.006.

[19] Fujishiro SH, Nakano K, Mizukami Y, Azami T, Arai Y, Matsunari H et al. Generation of naive-like porcine-induced pluripotent stem cells capable of contributing to embryonic and fetal development. Stem Cells Dev. 2013;22(3):473–82. doi:10.1089/scd.2012.0173.

[20] Fang R, Liu K, Zhao Y, Li H, Zhu D, Du Y et al. Generation of naive induced pluripotent stem cells from rhesus monkey fibroblasts. Cell Stem Cell. 2014;15(4):488–96. doi:10.1016/j.stem.2014.09.004.

[21] Honsho K, Hirose M, Hatori M, Yasmin L, Izu H, Matoba S et al. Naive-like conversion enhances the difference in innate in vitro differentiation capacity between rabbit ES cells and iPS cells. J Reprod Dev. 2015;61(1):13–9. doi:10.1262/jrd.2014-098.

[22] Mak SS, Alev C, Nagai H, Wrabel A, Matsuoka Y, Honda A et al. Characterization of the finch embryo supports evolutionary conservation of the naive stage of development in amniotes. Elife. 2015;4:e07178. doi:10.7554/eLife.07178.

[23] Kawaguchi T, Tsukiyama T, Kimura K, Matsuyama S, Minami N, Yamada M et al. Generation of Naive Bovine Induced Pluripotent Stem Cells Using PiggyBac Transposition of Doxycycline-Inducible Transcription Factors. PLoS One. 2015;10(8):e0135403. doi:10.1371/journal.pone.0135403.

[24] Hanna J, Cheng AW, Saha K, Kim J, Lengner CJ, Soldner F et al. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci U S A. 2010;107(20):9222–7. doi:10.1073/pnas.1004584107.

[25] Chan YS, Goke J, Ng JH, Lu X, Gonzales KA, Tan CP et al. Induction of a human pluripotent state with distinct regulatory circuitry that resembles preimplantation epiblast. Cell Stem Cell. 2013;13(6):663–75. doi:10.1016/j.stem.2013.11.015.

[26] Gafni O, Weinberger L, Mansour AA, Manor YS, Chomsky E, Ben-Yosef D et al. Derivation of novel human ground state naive pluripotent stem cells. Nature. 2013;504(7479):282–6. doi:10.1038/nature12745.

[27] Takashima Y, Guo G, Loos R, Nichols J, Ficz G, Krueger F et al. Resetting transcription factor control circuitry toward ground-state pluripotency in human. Cell. 2014;158(6):1254–69. doi:10.1016/j.cell.2014.08.029.

[28] Theunissen TW, Powell BE, Wang H, Mitalipova M, Faddah DA, Reddy J et al. Systematic identification of culture conditions for induction and maintenance of naive human pluripotency. Cell Stem Cell. 2014;15(4):471–87. doi:10.1016/j.stem.2014.07.002.
[29] Valamehr B, Robinson M, Abujarour R, Rezner B, Vranceanu F, Le T et al. Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells. Stem Cell Reports. 2014;2(3):366–81. doi:10.1016/j.stemcr.2014.01.014.

[30] Ware CB, Nelson AM, Mecham B, Hesson J, Zhou W, Jonlin EC et al. Derivation of naive human embryonic stem cells. Proc Natl Acad Sci U S A. 2014;111(12):4484–9. doi:10.1073/pnas.1319738111.

[31] Duggal G, Warrier S, Ghimire S, Broekaert D, Van der Jeught M, Lierman S et al. Alternative routes to induce naive pluripotency in human embryonic stem cells. Stem Cells. 2015;33(9):2686–98. doi:10.1002/stem.2071.

[32] Carter MG, Smagghe BJ, Stewart AK, Rapley JA, Lynch E, Bernier KJ et al. A Primitive Growth Factor, NME7AB, Is Sufficient to Induce Stable Naive State Human Pluripotency; Reprogramming in This Novel Growth Factor Confers Superior Differentiation. Stem Cells. 2016;34(4):847–59. doi:10.1002/stem.2261.

[33] Buecker C, Chen HH, Polo JM, Daheron L, Bu L, Barakat TS et al. A murine ESC-like state facilitates transgenesis and homologous recombination in human pluripotent stem cells. Cell Stem Cell. 2010;6(6):535–46. doi:10.1016/j.stem.2010.05.003.

[34] Yang Y, Zhang X, Yi L, Hou Z, Chen J, Kou X et al. Naive induced pluripotent stem cells generated from beta-Thalassemia fibroblasts allow efficient gene correction With CRISPR/Cas9. Stem Cells Transl Med. 2016;5(1):267. doi:10.5966/sctm.2015-0157erratum.

[35] Wang J, Xie G, Singh M, Ghanbarian AT, Rasko T, Szvetnik A et al. Primate-specific endogenous retrovirus-driven transcription defines naive-like stem cells. Nature. 2014;516(7531):405–9. doi:10.1038/nature13804.

[36] Osafune K, Caron L, Borowiak M, Martinez RJ, Fitz-Gerald CS, Sato Y et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol. 2008;26(3):313–5. doi:10.1038/nbt1383.

[37] Kim K, Zhao R, Doi A, Ng K, Unternaehrer J, Cahan P et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol. 2011;29(12):1117–9. doi:10.1038/nbt.2052.

[38] Kyttala A, Moraghebi R, Valensisi C, Kettunen J, Andrus C, Pasumarthy KK et al. Genetic variability overrides the impact of parental cell type and determines iPSC differentiation potential. Stem Cell Reports. 2016;6(2):200–12. doi:10.1016/j.stemcr.2015.12.009.

[39] Lee JH, Lee JB, Shapovalova Z, Fiebig-Comyn A, Mitchell RR, Laronde S et al. Somatic transcriptome priming gates lineage-specific differentiation potential of human-induced pluripotent stem cell states. Nat Commun. 2014;5:5605. doi:10.1038/ncomms6605.
[40] Irie N, Weinberger L, Tang WW, Kobayashi T, Viukov S, Manor YS et al. SOX17 is a critical specifier of human primordial germ cell fate. Cell. 2015;160(1-2):253–68. doi: 10.1016/j.cell.2014.12.013.

[41] Zwaka TP, Thomson JA. Homologous recombination in human embryonic stem cells. Nat Biotechnol. 2003;21(3):319–21. doi:10.1038/nbt788.

[42] Hu Z, Pu J, Jiang H, Zhong P, Qiu J, Li F et al. Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson’s Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling. Stem Cells Dev. 2015;24(21):2591–604. doi: 10.1089/scd.2015.0079.

[43] Galupa R, Heard E. X-chromosome inactivation: new insights into cis and trans regulation. Curr Opin Genet Dev. 2015;31:57–66. doi:10.1016/j.gde.2015.04.002.

[44] Lessing D, Anguera MC, Lee JT. X chromosome inactivation and epigenetic responses to cellular reprogramming. Annu Rev Genomics Hum Genet. 2013;14:85–110. doi: 10.1146/annurev-genom-091212-153530.

[45] Migeon BR, Wolf SF, Axelman J, Kaslow DC, Schmidt M. Incomplete X chromosome dosage compensation in chorionic villi of human placenta. Proc Natl Acad Sci U S A. 1985;82:3390–4.

[46] Disteche CM. Escape from X inactivation in human and mouse. Trends Genet. 1995;11(1):17–22.

[47] Okamoto I, Patrat C, Thepot D, Peynot N, Fauque P, Daniel N et al. Eutherian mammals use diverse strategies to initiate X-chromosome inactivation during development. Nature. 2011;472(7343):370–4. doi:10.1038/nature09872.

[48] Goldson E, Hagerman RJ. The fragile X syndrome. Dev Med Child Neurol. 1992;34(9):826–32.

[49] Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D et al. DNA methylation represses FMR‐1 transcription in fragile X syndrome. Hum Mol Genet. 1992;1(6):397–400.

[50] Coffee B, Zhang F, Ceman S, Warren ST, Reines D. Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome. Am J Hum Genet. 2002;71(4):923–32. doi:10.1086/342931.

[51] Usdin K, Kumari D. Repeat-mediated epigenetic dysregulation of the FMR1 gene in the fragile X-related disorders. Front Genet. 2015;6:192. doi:10.3389/fgen.2015.00192.

[52] Brouwer JR, Mientjes EJ, Bakker CE, Nieuwenhuizen IM, Severijnen LA, Van der Linde HC et al. Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res. 2007;313(2):244–53. doi:10.1016/j.yexcr.2006.10.002.
[53] Entezam A, Biacsi R, Orrison B, Saha T, Hoffman GE, Grabczyk E et al. Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model. Gene. 2007;395(1-2):125–34. doi:10.1016/j.gene.2007.02.026.

[54] Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, Amit A et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell. 2007;1(5):568–77. doi:10.1016/j.stem.2007.09.001.

[55] Avitzour M, Mor-Shaked H, Yanovsky-Dagan S, Aharoni S, Altarescu G, Renbaum P et al. FMR1 epigenetic silencing commonly occurs in undifferentiated fragile X-affected embryonic stem cells. Stem Cell Rep. 2014;3(5):699–706. doi:10.1016/j.stemcr.2014.09.001.

[56] Colak D, Zaninovic N, Cohen MS, Rosenwaks Z, Yang WY, Gerhardt J et al. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science. 2014;343(6174):1002–5. doi:10.1126/science.1245831.

[57] Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell. 2010;6(5):407–11. doi:10.1016/j.stem.2010.04.005.
